CA3142355A1 - Modified release formulations and uses thereof - Google Patents

Modified release formulations and uses thereof Download PDF

Info

Publication number
CA3142355A1
CA3142355A1 CA3142355A CA3142355A CA3142355A1 CA 3142355 A1 CA3142355 A1 CA 3142355A1 CA 3142355 A CA3142355 A CA 3142355A CA 3142355 A CA3142355 A CA 3142355A CA 3142355 A1 CA3142355 A1 CA 3142355A1
Authority
CA
Canada
Prior art keywords
amisulpride
less
pharmaceutical composition
weight
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142355A
Other languages
English (en)
French (fr)
Inventor
Takumi Asada
Gerald R. GALLUPPI
Seth Cabot Hopkins
Megumi Maruyama
Siriporn Toongsuwan
Yuki Tsushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of CA3142355A1 publication Critical patent/CA3142355A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3142355A 2019-06-04 2020-06-04 Modified release formulations and uses thereof Pending CA3142355A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962856952P 2019-06-04 2019-06-04
US62/856,952 2019-06-04
US201962872623P 2019-07-10 2019-07-10
US62/872,623 2019-07-10
US201962944023P 2019-12-05 2019-12-05
US62/944,023 2019-12-05
PCT/US2020/036118 WO2020247627A1 (en) 2019-06-04 2020-06-04 Modified release formulations and uses thereof

Publications (1)

Publication Number Publication Date
CA3142355A1 true CA3142355A1 (en) 2020-12-10

Family

ID=73651059

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142355A Pending CA3142355A1 (en) 2019-06-04 2020-06-04 Modified release formulations and uses thereof

Country Status (13)

Country Link
US (3) US11160758B2 (enExample)
EP (1) EP3980009A4 (enExample)
JP (1) JP2022535893A (enExample)
KR (1) KR20220018004A (enExample)
CN (1) CN114401717A (enExample)
AU (1) AU2020286441A1 (enExample)
BR (1) BR112021024380A2 (enExample)
CA (1) CA3142355A1 (enExample)
IL (1) IL288372A (enExample)
MX (1) MX2021014774A (enExample)
PH (1) PH12021553056A1 (enExample)
SG (1) SG11202113266YA (enExample)
WO (1) WO2020247627A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2020247603A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
WO2024086306A1 (en) * 2022-10-19 2024-04-25 Vitakey Inc. Formulated food products
CN115487161B (zh) * 2022-11-18 2023-03-03 山东则正医药技术有限公司 一种氨磺必利片的制备方法

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
AT264666B (de) 1965-06-10 1968-09-10 Elektroprojekt Berlin Veb Schaltungsanordnung zur automatischen Stillsetzung von Umkehr- und Einwegbandwalzgerüsten
US3577514A (en) 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
FR2415099A1 (fr) 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US4590062A (en) 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
IT1200178B (it) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
JP2572673B2 (ja) 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5591455A (en) 1990-12-20 1997-01-07 Warner-Jenkinson Company, Inc. Wet powder film-forming compositions
DE69132166T2 (de) 1990-12-20 2000-12-21 Warner-Jenkinson Co. Inc., St. Louis Filmbildende zusammensetzungen aus feuchtem pulver
GB2256648B (en) 1991-05-29 1995-08-30 Colorcon Ltd Wax polish composition
EP0520119A1 (de) 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
TW245641B (enExample) 1993-04-26 1995-04-21 Takeda Pharm Industry Co
WO1997044025A1 (en) 1996-05-23 1997-11-27 G.D. Searle & Co. Pharmaceutical compositions containing non-racemic verapamil and process for optimizing the pharmaceutical activity of r- and s-verapamil
US5877183A (en) 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
IT1283124B1 (it) 1996-06-12 1998-04-07 Prodotti Antibiotici Spa Forme e composizioni farmaceutiche per il trattamento dell'ipertrofia prostatica benigna
FR2753376B1 (fr) 1996-09-18 1998-10-16 Synthelabo Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
JP2001501207A (ja) 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US20010046473A1 (en) 1997-04-18 2001-11-29 Jerome Besse Gastric-retained pharmaceutical composition and method for its use
FR2762213B1 (fr) 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
ES2172944T3 (es) 1997-12-05 2002-10-01 Alza Corp Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
IL142778A0 (en) 1998-12-02 2002-03-10 Darwin Discovery Ltd Therapeutic product and its use
US6897242B1 (en) 1999-02-24 2005-05-24 Judson J. Somerville Non-racemic mixtures of d- and l- methadone and method of treating pain
MXPA03006003A (es) 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
US20030096264A1 (en) 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US20040204469A1 (en) 2001-06-19 2004-10-14 Norbert Muller Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20110130390A1 (en) 2001-06-19 2011-06-02 Mueller Norbert Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders
US20060167074A1 (en) 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US20050250767A1 (en) 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2004103262A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
FR2857263B1 (fr) 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
WO2005021039A1 (en) 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
EP1547650A1 (en) 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0507250A (pt) 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
JP2007526328A (ja) 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
FR2877573B1 (fr) 2004-11-05 2007-02-02 Debussy Holding Sa Nouvelles compositions pharmaceutiques et leurs utilisations pour lutter contre les differentes formes d'accoutumance aux drogues
US20060150989A1 (en) 2005-01-12 2006-07-13 Peter Migaly Method of diagnosing, treating and educating individuals with and/or about depression
US20060167068A1 (en) 2005-01-26 2006-07-27 Seth Feuerstein Method of treating self-injurious behavior with glutamate modulating agents
KR20070096058A (ko) 2005-01-28 2007-10-01 쉬바르츠파르마에이지 정신분열증의 부가 요법용 ｓｐｍ 927
US20110015246A2 (en) 2005-03-14 2011-01-20 Agean Llc Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis
MX2007012463A (es) 2005-04-08 2007-11-07 Pfizer Prod Inc Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
EP1948271B1 (en) 2005-11-17 2013-10-02 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
US20110136742A1 (en) 2006-02-24 2011-06-09 Travis Mickle Antidepressant prodrugs
US20100234288A1 (en) 2006-03-27 2010-09-16 Panacea Biotec Ltd SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A pH-DEPENDENT POLYMER
JP2009536164A (ja) 2006-05-10 2009-10-08 エボニック デグサ ゲーエムベーハー ロール圧密成形した熱分解法二酸化ケイ素の医薬組成物での使用
CA2652300A1 (en) 2006-05-15 2007-11-22 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
WO2007137224A2 (en) 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Method of treatment
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US8076075B2 (en) 2006-10-17 2011-12-13 The Research Foundation For Mental Hygiene, Inc. System and method for diagnosis of neuropsychiatric disorders
EP2077860B1 (en) 2006-10-25 2014-04-09 Ramot at Tel-Aviv University Ltd Psychotropic agents having glutamate nmda activity
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
EP1946777A1 (en) 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline for preventing weight gain
EP1944295A1 (en) 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Non-racemic mixtures of (R)-N-piperidinyl-5-(4-chlorophenyl)1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide
EP2457571A1 (en) 2007-02-01 2012-05-30 Alan I. Green Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
GB0707127D0 (en) 2007-04-13 2007-05-23 Zysis Ltd Pharmaceutical compositions
US20080280886A1 (en) 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
EP2030619A1 (en) 2007-06-18 2009-03-04 A.Carlsson Research AB Use of dopamine stabilizers
US20100197712A1 (en) 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
WO2009017453A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2009039461A2 (en) 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
JPWO2009057199A1 (ja) 2007-10-31 2011-03-10 財団法人乙卯研究所 レチノイドプロドラッグ化合物
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
CN101983058A (zh) 2008-02-05 2011-03-02 克莱拉有限公司 缓解抑郁症或改善认知的组合物和方法
US20090208979A1 (en) 2008-02-14 2009-08-20 Technion Research And Development Foundation Ltd. Method for identifying antipsychotic drug candidates
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20090269770A1 (en) 2008-04-24 2009-10-29 Technion Research And Development Foundation Ltd. Methods for evaluation prognosis and follow-up of drug treatment of psychiatric diseases or disorders
WO2010020642A1 (en) 2008-08-20 2010-02-25 Brainco Biopharma, S.L. Stxbp1 as psychiatric biomarker in murine model system and their uses
US20100074973A1 (en) 2008-08-27 2010-03-25 Auspex Pharmaceuticals, Inc. Thioxanthene modulators of dopamine d2 receptors
WO2010023690A2 (en) 2008-08-28 2010-03-04 Torrent Pharmaceuticals Ltd. Prolonged release formulation of amisulpride
US20100069399A1 (en) 2008-09-15 2010-03-18 Auspex Pharmaceutical, Inc. Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors
US20100119622A1 (en) 2008-09-15 2010-05-13 Auspex Pharmaceuticals, Inc. 3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor
WO2010033270A1 (en) 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
US20100119624A1 (en) 2008-09-17 2010-05-13 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor and/or 5-ht2a receptor
US20100266711A1 (en) 2008-09-29 2010-10-21 Auspex Pharmaceuticals, Inc. Thienobenzodiazepine modulators of d1 receptor, d2 receptor, and/or 5-ht2 receptor
US20100159033A1 (en) 2008-09-29 2010-06-24 Auspex Pharmaceuticals, Inc. Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
MX2011004994A (es) 2008-11-14 2011-09-28 Y Sk Chemicals Co Ltd Ewha University Industry Collaboration Foundation Metodo para preparar microesferas y microesferas producidas por el mismo.
WO2010058314A1 (en) 2008-11-18 2010-05-27 Pfizer Inc. Hydroxyquinolin-2(1h)-ones and derivatives thereof
CA2646779A1 (en) 2008-11-25 2010-05-25 Gerard Voon Bioscience ix
US20100143507A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
WO2010075275A1 (en) 2008-12-23 2010-07-01 Usworldmeds Llc Selective release of non-racemic mixtures of two enantiomers from tablets and capsules
MX353752B (es) 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
US8579865B2 (en) 2009-03-20 2013-11-12 Antares Pharma, Inc. Hazardous agent injection system
CN101898991B (zh) 2009-05-31 2013-09-25 江苏天士力帝益药业有限公司 一种(s)(-)-氨磺必利d-(-)-酒石酸盐的合成方法
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
GEP20115310B (en) 2009-10-09 2011-10-25 Medicinal preparation of amisulpride in the solid form and the method of its manufacture
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
US20110117214A1 (en) 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
WO2011143534A1 (en) 2010-05-13 2011-11-17 The Mclean Hospital Corporation Methods for the treatment of psychiatric disorders
EP2582665A1 (en) 2010-06-17 2013-04-24 Lupin Limited An improved process for preparation of amisulpride
WO2012002583A1 (en) 2010-07-02 2012-01-05 Vanderbilt University Method for treating schizophrenia and related diseases with a combination therapy
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
JP2013540748A (ja) 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
CA2816609A1 (en) 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
WO2012065110A2 (en) 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-protected cysteine analogs and related compounds
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルａｐｉローディングプロドラッグ
WO2012118562A1 (en) 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
CA2836066A1 (en) 2011-05-13 2012-11-22 Dainippon Sumitomo Pharma Co., Ltd. Treatment and management of cns disorders
BR112013033417A2 (pt) 2011-06-29 2016-08-16 Otsuka Pharma Co Ltd compostos terapêuticos e métodos relacionados de uso
EP2736890A4 (en) 2011-07-28 2015-07-15 Promentis Pharm Inc Cysteine PRODRUGS
WO2013040164A1 (en) 2011-09-13 2013-03-21 Biomed Valley Discoveries, Inc. Compositions and methods for treating metabolic disorders
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN102600132B (zh) 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN112402421A (zh) 2012-10-25 2021-02-26 大塚制药株式会社 含有依匹唑派或其盐的预防和/或治疗剂
WO2014164754A1 (en) * 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
WO2014152965A2 (en) 2013-03-14 2014-09-25 The Children's Hospital Of Philadelphia Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
US20170027958A1 (en) 2013-04-02 2017-02-02 Themis Medicare Limited Fulvestrant compositions
US10098893B2 (en) 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US10125365B2 (en) 2014-02-05 2018-11-13 Yeda Research And Development Co. Ltd. Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2959895A1 (en) 2014-06-27 2015-12-30 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) Compositions comprising Phenylalanine and Leucine for use in the diagnosis and treatment of neurological disorders and symptoms thereof
ES2562684B1 (es) 2014-08-04 2017-02-06 Consejo Superior De Investigaciones Científicas (Csic) Método de monitorización de tratamiento antipsicótico
US11174514B2 (en) 2014-08-29 2021-11-16 Northwestern University Methods, kits, and devices utilizing HTR2C polymorphisms for diagnosing, prognosing, and treating psychiatric disorders in a patient
WO2016109359A1 (en) 2014-12-29 2016-07-07 Auspex Pharmaceuticals, Inc. Cyclopropyl dihydrobenzofuran modulators of melatonin receptors
US20160193151A1 (en) 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
CN104725292B (zh) 2015-03-23 2017-07-25 湖北荆江源制药股份有限公司 一种(s)(‑)‑氨磺必利的制备方法
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
ITUB20150635A1 (it) 2015-04-14 2016-10-14 Giuseppe Lotito Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore.
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders
MX2018002627A (es) 2015-09-18 2018-12-17 Gruenenthal Chemie Metodo de cristalizacion y biodisponibilidad.
CN106890129A (zh) * 2015-12-18 2017-06-27 健乔信元医药生技股份有限公司 环苄普林之延释剂型
TW201733599A (zh) 2016-02-17 2017-10-01 醫療法人社團滉志會 以發炎性疾病為對象之醫藥
WO2017149387A1 (en) 2016-03-04 2017-09-08 Sharon Anavi-Goffer Compositions of cb2 receptor selective agonists for treatment of mental disorders
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US20180118967A1 (en) * 2016-10-31 2018-05-03 Xerox Corporation Metal Nanoparticle Ink Compositions For Printed Electronic Device Applications
US11377421B2 (en) 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
US10259786B2 (en) 2016-11-28 2019-04-16 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
CN106995397B (zh) * 2016-12-12 2020-01-14 河北医科大学 R-氨磺必利药用盐、制备方法、晶型及其用途
CN107126422B (zh) 2017-03-02 2020-07-07 河北龙海药业有限公司 一种氨磺必利片剂及其制备方法
CN107049981A (zh) 2017-04-11 2017-08-18 深圳市泛谷药业股份有限公司 一种速释氨磺必利药物组合物及其制备方法
WO2018200381A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
AU2018379992B2 (en) * 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
CN109010300A (zh) 2018-10-24 2018-12-18 湖南洞庭药业股份有限公司 一种氨磺必利片及其制备方法
WO2020247603A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
JP2024520704A (ja) 2021-04-01 2024-05-24 サノビオン ファーマシューティカルズ インク アミスルプリドの結晶形態を製造するための方法

Also Published As

Publication number Publication date
PH12021553056A1 (en) 2023-09-11
JP2022535893A (ja) 2022-08-10
US11654113B2 (en) 2023-05-23
US20200383924A1 (en) 2020-12-10
CN114401717A (zh) 2022-04-26
EP3980009A1 (en) 2022-04-13
AU2020286441A1 (en) 2022-01-06
US11160758B2 (en) 2021-11-02
SG11202113266YA (en) 2021-12-30
US20220117899A1 (en) 2022-04-21
EP3980009A4 (en) 2023-07-05
BR112021024380A2 (pt) 2022-04-19
MX2021014774A (es) 2022-02-03
KR20220018004A (ko) 2022-02-14
US20230404924A1 (en) 2023-12-21
WO2020247627A1 (en) 2020-12-10
IL288372A (en) 2022-01-01
US12161758B2 (en) 2024-12-10

Similar Documents

Publication Publication Date Title
US12161758B2 (en) Modified release formulations and uses thereof
US12161623B2 (en) Nonracemic mixtures and uses thereof
US20220323409A1 (en) Modified release formulations and uses thereof
EA014707B1 (ru) Новая форма введения рацекадотрила
JP7724776B2 (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
TW202237084A (zh) 修飾釋放調配物及其用途
HK40064212A (en) Modified release formulations and uses thereof
TW200920348A (en) Combination of picotamide with nafronyl
HK40072206A (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
JP2004210775A (ja) ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の結晶の製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240530

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250529

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250929

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251119

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260716